{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:18:56Z","timestamp":1794331136322,"version":"4.9.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-73126-9","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:43:11Z","timestamp":1780598591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4\/6 inhibitor therapy"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6711-7287","authenticated-orcid":false,"given":"Mitchell J.","family":"Elliott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesu\u0301s","family":"Fuentes-Antra\u0301s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha C.","family":"Main","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8293-2635","authenticated-orcid":false,"given":"Aaron","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Weipert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geethika","family":"Yalamanchili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5832-1702","authenticated-orcid":false,"given":"June","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle B.","family":"Nadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7524-7911","authenticated-orcid":false,"given":"Hal K.","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-0540","authenticated-orcid":false,"given":"Lillian L.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6771-2999","authenticated-orcid":false,"given":"Philippe L.","family":"Bedard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1080-0998","authenticated-orcid":false,"given":"David W.","family":"Cescon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"73126_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold, M. et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 66, 15\u201323 (2022).","journal-title":"Breast"},{"key":"73126_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/jnci\/djae241","volume":"117","author":"M Marczyk","year":"2025","unstructured":"Marczyk, M. et al. Trends in breast cancer-specific death by clinical stage at diagnoses between 2000 and 2017. J. Natl. Cancer Inst. 117, 287\u2013295 (2025).","journal-title":"J. Natl. Cancer Inst."},{"key":"73126_CR3","doi-asserted-by":"publisher","first-page":"103756","DOI":"10.1016\/j.breast.2024.103756","volume":"76","author":"F Cardoso","year":"2024","unstructured":"Cardoso, F. et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast 76, 103756 (2024).","journal-title":"Breast"},{"key":"73126_CR4","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1200\/JCO.21.01392","volume":"39","author":"HJ Burstein","year":"2021","unstructured":"Burstein, H. J. et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J. Clin. Oncol. 39, 3959\u20133977 (2021).","journal-title":"J. Clin. Oncol."},{"key":"73126_CR5","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Breast Cancer. Version 3.2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419."},{"key":"73126_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s43018-020-0043-5","volume":"1","author":"DW Cescon","year":"2020","unstructured":"Cescon, D. W., Bratman, S. V., Chan, S. M. & Siu, L. L. Circulating tumor DNA and liquid biopsy in oncology. Nat. Cancer 1, 276\u2013290 (2020).","journal-title":"Nat. Cancer"},{"key":"73126_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00626-6","volume":"10","author":"O Amato","year":"2024","unstructured":"Amato, O., Giannopoulou, N. & Ignatiadis, M. Circulating tumor DNA validity and potential uses in metastatic breast cancer. NPJ Breast Cancer 10, 21 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"73126_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00783-2","volume":"11","author":"J Fuentes-Antr\u00e1s","year":"2025","unstructured":"Fuentes-Antr\u00e1s, J. et al. Personalized ctDNA monitoring in metastatic HR+\/HER2- breast cancer patients during endocrine and CDK4\/6 inhibitor therapy. NPJ Breast Cancer 11, 74 (2025).","journal-title":"NPJ Breast Cancer"},{"key":"73126_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/jnci\/djaa087","volume":"113","author":"B O\u2019Leary","year":"2021","unstructured":"O\u2019Leary, B. et al. Circulating tumor DNA markers for early progression on fulvestrant with or without palbociclib in ER+ advanced breast cancer. J. Natl. Cancer Inst. 113, 309\u2013317 (2021).","journal-title":"J. Natl. Cancer Inst."},{"key":"73126_CR10","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.annonc.2023.08.011","volume":"34","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9, F. et al. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Ann. Oncol. 34, 1003\u20131014 (2023).","journal-title":"Ann. Oncol."},{"key":"73126_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03215-x","volume":"9","author":"B Oleary","year":"2018","unstructured":"Oleary, B. et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat. Commun. 9, 896 (2018).","journal-title":"Nat. Commun."},{"key":"73126_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00218-8","volume":"7","author":"O Mart\u00ednez-S\u00e1ez","year":"2021","unstructured":"Mart\u00ednez-S\u00e1ez, O. et al. Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4\/6 inhibition and endocrine therapy. NPJ Breast Cancer 7, 8 (2021).","journal-title":"NPJ Breast Cancer"},{"key":"73126_CR13","doi-asserted-by":"publisher","first-page":"11419","DOI":"10.3390\/ijms241411419","volume":"24","author":"J Fuentes-Antr\u00e1s","year":"2023","unstructured":"Fuentes-Antr\u00e1s, J. et al. Real-world use of highly sensitive liquid biopsy monitoring in metastatic breast cancer patients treated with endocrine agents after exposure to aromatase inhibitors. Int. J. Mol. Sci. 24, 11419 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"73126_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz, L. H. et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur. J. Cancer 62, 132\u2013137 (2016).","journal-title":"Eur. J. Cancer"},{"key":"73126_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.20517\/cdr.2022.37","volume":"5","author":"SC Main","year":"2022","unstructured":"Main, S. C., Cescon, D. W. & Bratman, S. V. Liquid biopsies to predict CDK4\/6 inhibitor efficacy and resistance in breast cancer. Canc. Drug Resist. 5, 727\u2013748 (2022).","journal-title":"Canc. Drug Resist."},{"key":"73126_CR16","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/1878-0261.12727","volume":"14","author":"HT Chan","year":"2020","unstructured":"Chan, H. T. et al. Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy. Mol. Oncol. 14, 1719\u20131730 (2020).","journal-title":"Mol. Oncol."},{"key":"73126_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105286","volume":"10","author":"MJ Elliott","year":"2025","unstructured":"Elliott, M. J. et al. Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer. ESMO Open 10, 105286 (2025).","journal-title":"ESMO Open"},{"key":"73126_CR18","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1158\/2767-9764.CRC-25-0151","volume":"5","author":"SI Liang","year":"2025","unstructured":"Liang, S. I. et al. Methylation-based ctDNA tumor fraction changes predict long-term clinical benefit from immune checkpoint inhibitors in RADIOHEAD, a real-world pan-cancer study. Cancer Res. Commun. 5, 1384\u20131395 (2025).","journal-title":"Cancer Res. Commun."},{"key":"73126_CR19","first-page":"CD008792","volume":"2021","author":"RF Dear","year":"2013","unstructured":"Dear, R. F. et al. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst. Rev. 2021, CD008792 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"73126_CR20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","volume":"35","author":"MA Gouda","year":"2024","unstructured":"Gouda, M. A. et al. Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST). Ann. Oncol. 35, 267\u2013275 (2024).","journal-title":"Ann. Oncol."},{"key":"73126_CR21","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","volume":"23","author":"F-C Bidard","year":"2022","unstructured":"Bidard, F.-C. et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 23, 1367\u20131377 (2022).","journal-title":"Lancet Oncol."},{"key":"73126_CR22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2217\/fon-2022-1196","volume":"19","author":"N Turner","year":"2023","unstructured":"Turner, N. et al. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol. 19, 559\u2013573 (2023).","journal-title":"Future Oncol."},{"key":"73126_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2025.100442","volume":"10","author":"CD Rolfo","year":"2025","unstructured":"Rolfo, C. D. et al. Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: evidence from a real-world cohort of patients with advanced common solid malignancies. J. Liq. Biopsy 10, 100442 (2025).","journal-title":"J. Liq. Biopsy"},{"key":"73126_CR24","first-page":"1346","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J. Clin. Orthod. 38, 1346\u20131366 (2020).","journal-title":"J. Clin. Orthod."},{"key":"73126_CR25","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","volume":"142","author":"AC Wolff","year":"2018","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. Arch. Pathol. Lab. Med. 142, 1364\u20131382 (2018).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"73126_CR26","doi-asserted-by":"publisher","unstructured":"Abstract 6601: Analytical validation of a robust integrated genomic and epigenomic liquid biopsy for biomarker discovery, therapy selection, and response monitoring. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.am2023-6601 (2023).","DOI":"10.1158\/1538-7445.am2023-6601"},{"key":"73126_CR27","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1158\/1538-7445.AM2022-3758","volume":"82","author":"WW Greenwald","year":"2022","unstructured":"Greenwald, W. W. et al. Abstract 3758: Accurate epigenomic estimates of circulating tumor fraction in large-scale clinical data. Cancer Res. 82, 3758\u20133758 (2022).","journal-title":"Cancer Res."},{"key":"73126_CR28","doi-asserted-by":"publisher","first-page":"5936","DOI":"10.1158\/1538-7445.AM2025-5936","volume":"85","author":"A Gross","year":"2025","unstructured":"Gross, A. et al. Abstract 5936: Landscape of epigenomic tumor fraction in large pan-cancer cfDNA cohort. Cancer Res. 85, 5936\u20135936 (2025).","journal-title":"Cancer Res."},{"key":"73126_CR29","doi-asserted-by":"publisher","first-page":"6603","DOI":"10.1158\/1538-7445.AM2025-6603","volume":"85","author":"PC Fiaux","year":"2025","unstructured":"Fiaux, P. C. et al. Abstract 6603: Analytical validation of a new plasma-only bioinformatics classifier to identify variants from clonal hematopoiesis (CH) in cfDNA liquid biopsy assays. Cancer Res. 85, 6603\u20136603 (2025).","journal-title":"Cancer Res."},{"key":"73126_CR30","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1158\/1538-7445.AM2023-3135","volume":"83","author":"J Yen","year":"2023","unstructured":"Yen, J. et al. Abstract 3135: Validation of a bioinformatic model for classifying non-tumor variants in a cell-free DNA liquid biopsy assay. Cancer Res. 83, 3135\u20133135 (2023).","journal-title":"Cancer Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73126-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73126-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73126-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:31:10Z","timestamp":1784849470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73126-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73126"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73126-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.M.W. and G.Y. are employees and stockholders of Guardant Health. E.A. reports honoraria from Sandoz and Seagen and consulting fees from AstraZeneca and Novartis. M.B.N. reports speaker honoraria and consulting fees from Novartis and Exact Sciences, outside the scope of the submitted work. L.L.S. reports participation on scientific advisory boards for Merck, Pfizer, AstraZeneca, Roche, GlaxoSmithKline, Voronoi, Arvinas, Navire, Relay, Daiichi Sankyo, Amgen, Marengo, Medicenna, Tubulis, LTZ Therapeutics, Pangea, and Break Through Cancer; institutional clinical trial support from Novartis, Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, GlaxoSmithKline, Roche\/Genentech, AstraZeneca, Merck, Celgene, Astellas, Bayer, AbbVie, Amgen, Symphogen, Mirati, BioNTech, 23andMe, and EMD Serono; stock ownership by a spouse in Agios; and leadership roles held by a spouse at Treadwell Therapeutics. P.L.B. reports institutional research funding from Amgen, AstraZeneca, Bayer, Bicara, Bristol Myers Squibb, Genentech\/Roche, Gilead, GlaxoSmithKline, Lilly\/Loxo, Medicenna, Merck, Nektar, Novartis, PTC Therapeutics, Sanofi, Seagen, Servier, SignalChem Life Sciences, Takeda, and Zymeworks, and uncompensated honoraria or consultancy from Zymeworks, Lilly, Seattle Genetics, Merck, Amgen, Gilead, Janssen, and Repare. M.J.E. reports honoraria or consultancy from Gilead, Knight Therapeutics, and Roche. DWC reports consultancy and advisory relationships with AstraZeneca, Daiichi Sankyo, Exact Sciences, GenomeRx, Gilead, GlaxoSmithKline, Inivata\/NeoGenomics, Knight Therapeutics, Lilly, Merck, Novartis, Pfizer, Roche and SAGA; research funding to their institution from AstraZeneca, GenomeRx, Guardant Health, Grail, Gilead, GlaxoSmithKline, Inivata\/NeoGenomics, Knight, Merck, PearBio, Pfizer, ProteinQure, RayzeBio and Roche and SAGA. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7183"}}